



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN:L24294TN1995PLCO30698

Date: June 24, 2025

To

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001.	National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai – 400051.
Scrip Code: 532989	Scrip Code: BAFNAPH

Dear Sir/Madam,

Subject: Disclosure Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 – Retirement of Independent Director of the Company

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we hereby inform you that Mr. Palamadai Krishnan Sundaresan (DIN: 06954189) will be retiring as an Independent Director of the Company upon completion of his first term, with effect from close of business hours on June 24, 2025. Consequently, he will also cease to be the Chairman of the Audit Committee and a Member of the Nomination & Remuneration Committee of the Company.

Further, we wish to inform you that due to the change in composition of the Board of Directors, the Board of Directors has re-constituted the composition of the following Committees with effect from June 25, 2025, as detailed below:

Name of the Committee	Name of the Director	Designation & Category
Audit Committee	Mr. Navin Kumar	Chairman (Non-Executive, Independent)
	Mrs. Ravichandran Chitra	Member (Non-Executive, Independent)
	Mr. Upendar Mekala Reddy	Member (Non-Executive, Non-Independent)
Nomination and Remuneration Committee	Mrs. Ravichandran Chitra	Chairperson (Non-Executive, Independent)
	Mr. Navin Kumar	Member (Non-Executive, Independent)
	Mrs. Akila Chintalapati Raju	Member (Non-Executive, Non-Independent)



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN: L24294TN1995PLCO30698

Notwithstanding the aforesaid retirement of the Independent Director, the composition of the Board and its Committees continues to remain in compliance with the requirements of the applicable laws.

The disclosures as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are provided in **Annexure - I**.

We request you take the above information on record.

Thanking You.

For **BAFNA PHARMACEUTICALS LIMITED**

Mohanachandran A
Company Secretary & Compliance Officer

Enclosed: As Above



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN: L24294TN1995PLCO30698

Annexure - I

Disclosures as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 as under:

Sl. No.	Particulars	Description
1	Name of Director	Mr. Palamadai Krishnan Sundaresan
2	DIN	06954189
3	Reason for change	Retirement of Mr. Palamadai Krishnan Sundaresan, as Independent Director of the Company, upon completion of first term, with effect from June 24, 2025.
4	Date of Cessation	Close of Business Hours on June 24, 2025.
5	Brief Profile (in case of appointment)	Not Applicable
6	Disclosure of relationships between directors (in case of appointment)	Nil